Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Charlotte M. Niemeyer, Mignon L. Loh, Annamaria Cseh, Todd Cooper, Christopher C. Dvorak, Rebecca Chan, Blanca Xicoy, Ulrich Germing, Seiji Kojima, Atsushi Manabe, Michael Dworzak, Barbara De Moerloose, Jan Starý, Owen P. Smith, Riccardo Masetti, Albert Catala, Eva Bergstraesser, Marek Ussowicz, Oskana Fabri, André BaruchelHélène Cavé, Michel Zwaan, Franco Locatelli, Henrik Hasle, Marry M. Van Den Heuvel-Eibrink, Christian Flotho, Ayami Yoshimi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalHaematologica
Volume100
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Juvenile Myelomonocytic Leukemia
Clinical Trials
Hematopoietic Stem Cell Transplantation
Therapeutics
Phase II Clinical Trials
Chimerism
Clinical Trials, Phase I
Inborn Genetic Diseases
Rare Diseases
Platelet Count
Leukocyte Count
Cytogenetics
Spleen
Transplantation
Bone Marrow
Transplants
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. / Niemeyer, Charlotte M.; Loh, Mignon L.; Cseh, Annamaria; Cooper, Todd; Dvorak, Christopher C.; Chan, Rebecca; Xicoy, Blanca; Germing, Ulrich; Kojima, Seiji; Manabe, Atsushi; Dworzak, Michael; De Moerloose, Barbara; Starý, Jan; Smith, Owen P.; Masetti, Riccardo; Catala, Albert; Bergstraesser, Eva; Ussowicz, Marek; Fabri, Oskana; Baruchel, André; Cavé, Hélène; Zwaan, Michel; Locatelli, Franco; Hasle, Henrik; Van Den Heuvel-Eibrink, Marry M.; Flotho, Christian; Yoshimi, Ayami.

In: Haematologica, Vol. 100, No. 1, 2015, p. 17-22.

Research output: Contribution to journalArticle

Niemeyer, CM, Loh, ML, Cseh, A, Cooper, T, Dvorak, CC, Chan, R, Xicoy, B, Germing, U, Kojima, S, Manabe, A, Dworzak, M, De Moerloose, B, Starý, J, Smith, OP, Masetti, R, Catala, A, Bergstraesser, E, Ussowicz, M, Fabri, O, Baruchel, A, Cavé, H, Zwaan, M, Locatelli, F, Hasle, H, Van Den Heuvel-Eibrink, MM, Flotho, C & Yoshimi, A 2015, 'Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia', Haematologica, vol. 100, no. 1, pp. 17-22. https://doi.org/10.3324/haematol.2014.109892
Niemeyer, Charlotte M. ; Loh, Mignon L. ; Cseh, Annamaria ; Cooper, Todd ; Dvorak, Christopher C. ; Chan, Rebecca ; Xicoy, Blanca ; Germing, Ulrich ; Kojima, Seiji ; Manabe, Atsushi ; Dworzak, Michael ; De Moerloose, Barbara ; Starý, Jan ; Smith, Owen P. ; Masetti, Riccardo ; Catala, Albert ; Bergstraesser, Eva ; Ussowicz, Marek ; Fabri, Oskana ; Baruchel, André ; Cavé, Hélène ; Zwaan, Michel ; Locatelli, Franco ; Hasle, Henrik ; Van Den Heuvel-Eibrink, Marry M. ; Flotho, Christian ; Yoshimi, Ayami. / Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. In: Haematologica. 2015 ; Vol. 100, No. 1. pp. 17-22.
@article{2f360b1862544c1ab3e0b3d62e93f9f7,
title = "Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia",
abstract = "Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.",
author = "Niemeyer, {Charlotte M.} and Loh, {Mignon L.} and Annamaria Cseh and Todd Cooper and Dvorak, {Christopher C.} and Rebecca Chan and Blanca Xicoy and Ulrich Germing and Seiji Kojima and Atsushi Manabe and Michael Dworzak and {De Moerloose}, Barbara and Jan Star{\'y} and Smith, {Owen P.} and Riccardo Masetti and Albert Catala and Eva Bergstraesser and Marek Ussowicz and Oskana Fabri and Andr{\'e} Baruchel and H{\'e}l{\`e}ne Cav{\'e} and Michel Zwaan and Franco Locatelli and Henrik Hasle and {Van Den Heuvel-Eibrink}, {Marry M.} and Christian Flotho and Ayami Yoshimi",
year = "2015",
doi = "10.3324/haematol.2014.109892",
language = "English",
volume = "100",
pages = "17--22",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

AU - Niemeyer, Charlotte M.

AU - Loh, Mignon L.

AU - Cseh, Annamaria

AU - Cooper, Todd

AU - Dvorak, Christopher C.

AU - Chan, Rebecca

AU - Xicoy, Blanca

AU - Germing, Ulrich

AU - Kojima, Seiji

AU - Manabe, Atsushi

AU - Dworzak, Michael

AU - De Moerloose, Barbara

AU - Starý, Jan

AU - Smith, Owen P.

AU - Masetti, Riccardo

AU - Catala, Albert

AU - Bergstraesser, Eva

AU - Ussowicz, Marek

AU - Fabri, Oskana

AU - Baruchel, André

AU - Cavé, Hélène

AU - Zwaan, Michel

AU - Locatelli, Franco

AU - Hasle, Henrik

AU - Van Den Heuvel-Eibrink, Marry M.

AU - Flotho, Christian

AU - Yoshimi, Ayami

PY - 2015

Y1 - 2015

N2 - Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.

AB - Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84920147335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920147335&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.109892

DO - 10.3324/haematol.2014.109892

M3 - Article

C2 - 25552679

AN - SCOPUS:84920147335

VL - 100

SP - 17

EP - 22

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -